Ex vivo drug testing of patient-derived lung organoids to predict treatment responses for personalized medicine

Lung cancer remains the leading cause of cancer-related mortality worldwide accounting for approximately 1.8 million deaths in 2020 [1]. Non-small cell lung cancer (NSCLC) is the predominant histologic subtype, accounting for 85  % of all lung cancer cases in the United States [2]. In comparison, small cell lung cancer (SCLC) represents 15 % of lung cancer cases, occurs almost exclusively in smokers and has the most aggressive clinical course with survival outcomes of 2 to 4 months in untreated patients [3,4].

Source: Lung Cancer - March 13, 2024 Category: Cancer & Oncology Authors: Josephine A. Taverna, Chia-Nung Hung, Madison Williams, Ryan Williams, Meizhen Chen, Samaneh Kamali, Vaishnavi Sambandam, Cheryl Hsiang-Ling Chiu, Pawel A. Osmulski, Maria E. Gaczynska, Daniel T. DeArmond, Christine Gaspard, Maria Mancini, Meena Kusi, Abh Tags: Review article Source Type: research